Skip to content Skip to navigation

COVID-19 Response: Stanford University-Alloy Therapeutics License Agreement for Antibody Prototyping

Stanford University’s Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. The purpose of this license agreement is to leverage emerging capacity and infrastructure at Stanford to address the current COVID-19 pandemic.

COVID-19 Response: Antibody Prototyping

IMA seeks to support translational research projects that will develop antibody prototypes against COVID-19 by providing access to proprietary technologies from Alloy Therapeutics.

License Agreement

Stanford has obtained a worldwide, non-exclusive license to use the ATX Technology solely for antibody discovery for research, development, and commercialization in the field of COVID-19. This may include the following:

  • immunizing ATX-Gx transgenic humanized mice
  • isolating antibodies or cells that produce antibodies from the ATX-Gx mice
  • cloning of the antibodies isolated from the ATX-Gx mice
  • modification of the antibodies isolated from the ATX-Gx mice
  • in vitro and in vivo characterization of the antibodies and modified antibodies

Introduction to Alloy Therapeutics

Alloy Therapeutic’s ATX-Gx platform is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery

Alloy Gamma-Kappa (GK) Mouse:
A robust workhorse for in vivo antibody discovery and is the basis of the ATX-GX platform package:

  • 10 years in development, originally invented and validated inside a major Pharma company then further developed at Alloy
  • Complete functional human antibody repertoire - Gamma: 40+V, 23D, 6J Segments - Kappa: 19V, 5J Segments
  • Fully functional immune system – robust immune response that is equivalent to wild type mice
  • Available on multiple genetic backgrounds


ATX-GX mouse has been successful with a range of antigens

Alloy is expanding the ATX-Gx platforms:

  • ATX-GK+ line - incremental improvement to genetic background to optimize immunocompetence (available now)
  • ATX-pGK and ATX-dGK - heavy chain repertoire split between two separate lines to  overcome immunodominant germlines. Full kappa light chain diversity (in development)
  • ATX-GL – generating human Lambda antibodies (available now)

Alloy is also creating new platforms:

  • The ATX-CLC platform for bispecific antibody discovery - a proprietary suite of common light chain mice, available for beta testing in 2021


To learn how to access the Alloy Therapeutics platform, please contact:

Paul Humphries, Ph.D.
Alliance Director, Innovative Medicines Accelerator